REFERENCES
- Fink J S, Weaver D R, Rivkees S A, Peterfreund R A, Pollack A E, Adler E M, Reppert S M. Molecular cloning of the rat A2 adenosine receptor: Selective co-expression with D2 dopamine receptors in rat striatum. Brain Res 1992; 14: 186–195, [CSA]
- Schiffmann S N, Libert F, Vassart G, Vanderhaeghen J J. Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci Lett 1991; 130: 177–181, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Pollack A E, Fink J S. Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience 1995; 68: 721–728, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Jin S, Johansson B, Fredholm B B. Effects of adenosine A1 and A2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices. J Pharmacol Exp Ther 1993; 267: 801–808, [PUBMED], [INFOTRIEVE], [CSA]
- Corsi C, Melani A, Bianchi L, Pepeu G, Pedata F. Effect of adenosine A2A receptor stimulation on GABA release from the striatum of young and aged rats in vivo. Neuroreport 1999; 10: 3933–3937, [PUBMED], [INFOTRIEVE], [CSA]
- Mayfield R D, Larson G, Orona R A, Zahniser N R. Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: Evidence for an A2a/D2 receptor interaction in globus pallidus. Synapse (NY) 1996; 22: 132–138, [CSA], [CROSSREF], [CROSSREF]
- Zahniser N R, Simosky J K, Mayfield R D, Negri C A, Hanania T, Larson G A, Kelly M A, Grandy D K, Rubinstein M, Low M J, Fredholm B B. Functional uncoupling of adenosine A(2A) receptors and reduced responseto caffeine in mice lacking dopamine D2 receptors. J Neurosci 2004; 20: 5949–5957, [CSA]
- Aoyama S, Kase H, Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 2000; 20: 5848–5852, [PUBMED], [INFOTRIEVE], [CSA]
- Chen J F, Moratalla R, Impagnatiello F, Grandy D K, Cuellar B, Rubinstein M, Beilstein M A, Hackett E, Fink J S, Low M J, Ongini E, Schwarzschild MA. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci USA 2001; 98: 1970–1975, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Fredduzzi S, Moratalla R, Monopoli A, Cuellar B, Xu K, Ongini E, Impagnatiello F, Schwarzschild M A, Chen J-F. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci 2002; 22: 1054–1062, [PUBMED], [INFOTRIEVE], [CSA]
- Chen J F, Xu K, Petzer J P, Staal R, Xu Y H, Beilstein M, Sonsalla P K, Castagnoli K, Castagnoli N, Jr., Schwarzschild MA. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001; 21: RC143, [PUBMED], [INFOTRIEVE], [CSA]
- Grondin R, Bedard P J, Hadj Tahar A, Gregoire L, Mori A, Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 1999; 52: 1673–1677, [PUBMED], [INFOTRIEVE], [CSA]
- Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 2002; 80: 262–270, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Ongini E, Monopoli A, Impagnatiello F, Fredduzzi S, Schwarzschild M, Chen J-F. Dual actions of A2A adenosine receptor antagonists on motor dysfunction and neurodegenerative processes. Drug Dev Res 2001; 52: 379–386, [CSA], [CROSSREF], [CROSSREF]
- Ferre S, von Euler G, Johansson B, Fredholm B B, Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA 1991; 88: 7238–7241, [PUBMED], [INFOTRIEVE], [CSA]
- Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah M E, Mallol J, Canela E I, Zoli M, Agnati L F, Ibanez C F, Lluis C, Franco R, Ferre S, Fuxe K. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 2002; 277: 18091–18097, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Kudlacek O, Just H, Korkhov V M, Vartian N, Klinger M, Pankevych H, Yang Q, Nanoff C, Freissmuth M, Boehm S. The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells. Neuropsychopharmacology 2003; 28: 1317–1327, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Vortherms T A, Watts V J. Sensitization of neuronal A2A adenosine receptors after persistent D2 dopamine receptor activation. J Pharmacol Exp Ther 2004; 308: 221–227, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Canals M, Marcellino D, Fanelli F, Ciruela F, De Benedetti P, Goldberg S R, Neve K, Fuxe K, Agnati L F, Woods A S, Ferre S, Lluis C, Bouvier M, Franco R. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 2003; 278: 46741–46749, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Kamiya T, Saitoh O, Yoshioka K, Nakata H. Oligomerization of adenosine A2A and dopamine D2 receptors in living cells. Biochem Biophys Res Commun 2003; 306: 544–549, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Lindskog M, Svenningsson P, Pozzi L, Kim Y, Fienberg A A, Bibb J A, Fredholm B B, Nairn A C, Greengard P, Fisone G. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature (Lond) 2002; 418: 774–778, [CSA], [CROSSREF], [CROSSREF]
- Svenningsson P, Tzavara E T, Carruthers R, Rachleff I, Wattler S, Nehls M, Mc Kinzie D L, Fienberg A A, Nomikos G G, Greengard P. Diverse Psychotomimetics act through a common signaling pathway. Science 2003; 302: 1412–1415, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Svenningsson P, Lindskog M, Ledent C, Parmentier M, Greengard P, Fredholm B B, Fisone G. Regulation of the phosphorylation of the dopamine-and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, adenosine A2A receptors. Proc Natl Acad Sci USA 2000; 97: 1856–1860, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Tang Y, Luo J, Fleming C R, Kong Y, Olini G C, Wildey M J, Cavender D E, Demarest K T. Development of a sensitive and HTS-compatible reporter gene assay for functional anal. of human adenosine A2a receptors in CHO-K1 cells. Assay Drug Dev Techn 2004; 2: 281–289, [CSA], [CROSSREF], [CROSSREF]
- Malmberg A, Mohell N. Characterization of [3H]quinpirole binding to human dopamine D2A and D3 receptors: Effects of ions and guanine nucleotides. J Pharmacol Exp Ther 2005; 274: 790–797, [CSA]
- Chen W, Shields T S, Stork P J, Cone R D. A colorimetric assay for measuring activation of Gs- and Gq-coupled signaling pathways. Anal Biochem 1995; 226: 349–354, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Klotz K N. Adenosine receptors and their ligands. N-S Arch Pharmacol 2000; 362: 382–391, [CSA], [CROSSREF], [CROSSREF]
- Lefkowitz R J. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem 1998; 273: 18677–18680, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Jang I S, Juhnn Y S. Adaptation of cAMP signaling system in SH-SY5Y neuroblastoma cells following expression of a constitutively active stimulatory G protein alpha, Q227L Gsalpha. Exp Mol Med 2001; 33: 37–45, [PUBMED], [INFOTRIEVE], [CSA]
- Sunahara R K, Dessauer C W, Gilman A G. Complexity and diversity of mammalian adenylyl cyclases. Ann Rev Pharmacol 1996; 36: 461–480, [CSA], [CROSSREF], [CROSSREF]
- Watts V J. Molecular mechanisms for heterologous sensitization of adenylate cyclase. J Pharmacol Exp Ther 2002; 302: 1–7, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Salim H, Ferre S, Dalal A, Peterfreund R A, Fuxe K, Vincent J D, Lledo P M. Activation of adenosine A1 and A2A receptors modulates dopamine D2 receptor-induced responses in stably transfected human neuroblastoma cells. J Neurochem 2000; 74: 432–439, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Palmer T M, Gettys T W, Jacobson K A, Stiles G L. Desensitization of the canine A2a adenosine receptor: Delineation of multiple processes. Mol Pharmacol 1994; 45: 1082–1094, [PUBMED], [INFOTRIEVE], [CSA]
- Mundell S J, Kelly E. Evidence for co-expression and desensitization of A2a and A2b adenosine receptors in NG108-15 cells. Biochem Pharmacol 1998; 55: 595–603, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Ng G Y, Varghese G, Chung H T, Trogadis J, Seeman P, O'Dowd B F, George S R. Resistance of the dopamine D2L receptor to desensitization accompanies the up-regulation of receptors on to the surface of Sf9 cells. Endocrinology 1997; 138: 4199–4206, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Mundell S J, Benovic J L, Kelly E A. dominant negative mutant of the G protein-coupled receptor kinase 2 selectively attenuates adenosine A2 receptor desensitization. Mol Pharmacol 1997; 51: 991–998, [PUBMED], [INFOTRIEVE], [CSA]
- Standaert D G, Young A B. Treatment of central nervous system degenerative diseases. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. McGraw-Hill, New York 1996; 503–519
- Sharma S K, Klee W A, Nirenberg M. Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance. Proc Natl Acad SciUSA 1975; 72: 3092–3096, [CSA]
- Avidor-Reiss T, Nevo I, Saya D, Bayewitch M, Vogel Z. Opiate-induced adenylyl cyclase superactivation is isozyme-specific. J Biol Chem 1997; 272: 5040–5047, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Nevo I, Avidor-Reiss T, Levy R, Bayewitch M, Vogel Z. Acute and chronic activation of the mu-opioid receptor with the endogenous ligand endomorphin differentially regulates adenylyl cyclase isozymes. Neuropharmacology 2000; 39: 364–371, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Thomas J M, Hoffman B B. Isoform-specific sensitization of adenylyl cyclase activity by prior activation of inhibitory receptors: Role of beta gamma subunits in transducing enhanced activity of the type VI isoform. Mol Pharmacol 1996; 49: 907–914, [PUBMED], [INFOTRIEVE], [CSA]
- Ammer H, Schulz R. Enhanced stimulatory adenylyl cyclase signaling during opioid dependence is associated with a reduction in palmitoylated Gs alpha. Mol Pharmacol 1997; 52: 993–999, [PUBMED], [INFOTRIEVE], [CSA]
- Toki S, Donati R J, Rasenick M M. Treatment of C6 glioma cells and rats with antidepressant drugs increases the detergent extraction of G(s alpha) from plasma membrane. J Neurochem 1999; 73: 1114–1120, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Vortherms T A, Nguyen C H, Berlot C H, Watts V J. Using molecular tools to dissect the role of Galphas in sensitization of AC1. Mol Pharmacol 2004; 66: 1617–1624, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Avidor-Reiss T, Nevo I, Levy R, Pfeuffer T, Vogel Z. Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gbetagamma. J Biol Chem 1996; 271: 21309–21315, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Rhee M H, Nevo I, Avidor-Reiss T, Levy R, Vogel Z. Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB(1) cannabinoid receptor. Mol Pharmacol 2000; 57: 746–752, [PUBMED], [INFOTRIEVE], [CSA]
- Sato M, Gettys Thomas W, Lanier Stephen M. AGS3 and signal integration by Galpha(s)- and Galpha(i)-coupled receptors: AGS3 blocks the sensitization of adenylyl cyclase following prolonged stimulation of a Galpha(i)-coupled receptor by influencing processing of Galpha(i). J Biol Chem 2004; 279: 13375–13382, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Johnston C A, Beazely M A, Vancura A F, Wang JKT, Watts V J. Heterologous sensitization of adenylate cyclase is protein kinase A-dependent in Cath.a differentiated (CAD)-D2L cells. J Neurochem 2002; 82: 1087–1096, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Glatt C E, Snyder S H. Cloning and expression of an adenylyl cyclase localized to the corpus striatum. Nature 1993; 361: 536–538, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Hanoune J, Pouille Y, Tzavara E, Shen T, Lipskaya L, Miyamoto N, Suzuki Y, Defer N. Adenylyl cyclases: Structure, regulation and function in an enzyme superfamily. Mol Cell Endocrinol 1997; 128: 179–194, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF], [CROSSREF]
- Lee K -W, Hong J -H, Choi I Y, Che Y, Lee J-K, Yang S-D, Song C-W, Kang H S, Lee J-H, Noh J S, Shin H-S, Han P-L. Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase. J Neurosci 2002; 22: 7931–7940, [PUBMED], [INFOTRIEVE], [CSA]
- Kanda T, Jackson M J, Smith L A, Pearce RKB, Nakamura J, Kase H, Kuwana Y, Jenner P. Combined use of the adenosine A2A antagonist KW-6002 with l-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000; 162: 321–327, [PUBMED], [INFOTRIEVE], [CSA]